No Data
Stocks to Watch: Rumble, Lexicon Pharmaceuticals
FDA Rejects Lexicon's Zynquista for Diabetes, Kidney Disease
Lexicon Fails to Secure FDA Approval for Zynquista -- Shares Fall After Hours
Express News | Lexicon Pharmaceuticals Inc - to Discontinue Zynquista Launch Preparations
Express News | Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (Sotagliflozin)
Lexicon Announces Receipt of Complete Response Letter for Zynquista (Sotagliflozin)
Lnova : Oh wait fda rejected?
Lnova :
Jaguar8 OP Lnova : CRL
Lnova Jaguar8 OP : Gotcha. But Lex is discontinuing it? They are scrapping it?
Jaguar8 OP Lnova : I think that was their decision after the CRL.
View more comments...